The administration of recombinant GM-CSF worsened the disease in EAE [94] and elevated concentrations of GM-CSF have been reported in the cerebrospinal fluid but not in the serum of patients with relapsing-remitting or secondary progressive MS [96, 97]. This evidence concerns the gene CSF2 and secondary progressive multiple sclerosis.